Patents by Inventor Chandrani CHATTOPADHYAY

Chandrani CHATTOPADHYAY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA
    Publication number: 20240068047
    Abstract: Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and/or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.
    Type: Application
    Filed: September 7, 2023
    Publication date: February 29, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: Chandrani CHATTOPADHYAY, Janos ROSZIK
  • Use of SDHA as a prognostic marker and therapeutic target in uveal melanoma
    Patent number: 11767564
    Abstract: Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and/or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: September 26, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Chandrani Chattopadhyay, Janos Roszik
  • USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA
    Publication number: 20200399704
    Abstract: Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and/or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.
    Type: Application
    Filed: October 25, 2018
    Publication date: December 24, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: Chandrani CHATTOPADHYAY, Janos ROSZIK